Identification of Candidate Tolerogenic CD8⁺ T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model

Figure 2

(a) High zone tolerance. Peptides were injected i.p. ( mice per group) beginning at 4 weeks of age as described in “Section 2.” Blood glucose was monitored from age of 13 to 31 weeks. Statistical comparison of peptide-treated groups to the control group receiving PBS at the last week was made by log-rank test (Mantel-Cox). These data are from a single experiment. (b) Peptide plus Zymosan A. Mice ( mice per group) having blood glucose ~170 mg/dL received a single injection of the indicated peptide admixed with Zymosan A as described in “Section 2” and were monitored for blood glucose. Control mice received Flu NP_147–155 peptide plus Zymosan. The experiment was repeated once and data were combined for statistical comparison to mice receiving control peptide (log-rank test). (c) and (d) DNA plasmid vaccination. Purified plasmids were injected in the quadriceps of NOD mice ( mice per group) beginning at 4 weeks of age as described in “Section 2.” Control mice received purified empty vector. Blood glucose was monitored. (c) shows mice receiving single plasmids and (d) shows mice receiving mixtures of plasmids as indicated. Data for the “control” and “insulin” groups is reproduced in each panel. The experiment was repeated once and data were combined for statistical comparison to mice receiving control plasmid (log-rank test).

(a)

(b)

(c)

(d)